Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Randomized, Multicenter, Open-Label, Phase 2 Study of VELCADE Alone or VELCADE Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.
Status | Completed |
Enrollment | 155 |
Est. completion date | |
Est. primary completion date | September 2004 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria - Inoperable, locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC that has been histologically or cytologically confirmed. - No more than 1 prior chemotherapy regimen. - 18 years of age or older. - Measurable or evaluable disease. - KPS =70%. - Life expectancy greater than 3 months. - Female patient is either post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control for the duration of the study. - Male patient agrees to use an acceptable method of birth control for the duration of the study. - Provide written informed consent before any study-related procedure not part of normal medical care is conducted. - Willing and able to comply with the protocol requirements. Exclusion Criteria - Peripheral neuropathy of Grade 2 or greater intensity, as defined by the NCI Common Toxicity Criteria (CTC): - Grade 2: Objective sensory loss or paresthesia (including tingling), interfering with function, but not interfering with activities of daily living (ADLs). - Grade 3: Sensory loss or paresthesia interfering with ADLs. - Grade 4: Permanent sensory loss that interferes with function. - Previous treatment with VELCADE. - Previous treatment with docetaxel (prior treatment with paclitaxel will be allowed). - Chemotherapy within 4 weeks prior to enrollment. - Radiation therapy within 4 weeks prior to enrollment. - Monoclonal antibodies within 6 weeks prior to enrollment. - Any major surgery within 4 weeks prior to enrollment. - Inadequate organ function at the Screening visit as defined by the following laboratory values: - Platelet count =100,000 x 109/L - Hemoglobin =8.0 g/dL - Absolute neutrophil count (ANC) =1.5 x 109/L - Aspartate transaminase (AST) =3 x the upper limit of the normal range (ULN) - Alanine transaminase (ALT) =3 times ULN - Creatinine =1.8 mg/dL - Total bilirubin =2 times ULN - Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant. - No history of brain metastases or central nervous system disease. - Active systemic infection requiring treatment. - Treatment for a cancer other than NSCLC within 5 years prior to enrollment, with the exception of basal cell carcinoma or cervical cancer in situ. - History of allergic reaction attributable to compounds containing boron or mannitol. - Known to be human immunodeficiency virus (HIV)-positive. Patients assessed by the investigator to be at risk for HIV infection should be tested in accordance with local regulations. - Known to be hepatitis B surface antigen-positive or has known active hepatitis C infection. Patients assessed by the investigator to be at risk for hepatitis B or C infection should be tested in accordance with local regulations. - Poorly controlled hypertension, diabetes mellitus, or another serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol. - Pregnant or breast-feeding female patient. Confirmation that the patient is not pregnant must be established by a negative serum ß-human chorionic gonadotropin (ß-hCG) pregnancy test result obtained during the Screening period. Pregnancy testing is not required for post-menopausal or surgically sterilized women. - Currently enrolled in another clinical research study or has received an investigational agent for any reason within 4 weeks of enrollment. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Winship Cancer Institute | Atlanta | Georgia |
United States | University of Colorado Health Sciences Center | Aurora | Colorado |
United States | U of Alambama at Birmingham Comprehensive Cancer Center | Birmingham | Alabama |
United States | Mass. General Hospital Hem/Onc. Associates | Boston | Massachusetts |
United States | Carolinas Hematology-Oncology Associates | Charlotte | North Carolina |
United States | Atlanta VAMC | Decatur | Georgia |
United States | Duke University Medical Center | Durham | North Carolina |
United States | Univeristy of Florida Shands Cancer Center | Gainesville | Florida |
United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | DBA Kansas City Cancer Centers | Kansas City | Missouri |
United States | Cedars-Sinai Comprehensive Cancer Center | Los Angeles | California |
United States | UCLA Medical Center Thoracic Malignancy | Los Angeles | California |
United States | University of Wisconsin Comprehensive Cancer Center | Madison | Wisconsin |
United States | Sylvester Comprehensive Cancer Center | Miami | Florida |
United States | Vanderbilt University-Clinical Trials Center | Nashville | Tennessee |
United States | Yale University School Of Medicine | New Haven | Connecticut |
United States | Kimmel Cancer Center at Jefferson | Philadelphia | Pennsylvania |
United States | Hunstman Cancer Institute-University of Utah | Salt Lake City | Utah |
United States | St. Louis University Health Sciences Center | St. Louis | Missouri |
United States | Washington University, Barnard Cancer Center | St. Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Millennium Pharmaceuticals, Inc. |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |